CY1113171T1 - Αντιφλεγμονωδεις παραγοντες - Google Patents

Αντιφλεγμονωδεις παραγοντες

Info

Publication number
CY1113171T1
CY1113171T1 CY20121100921T CY121100921T CY1113171T1 CY 1113171 T1 CY1113171 T1 CY 1113171T1 CY 20121100921 T CY20121100921 T CY 20121100921T CY 121100921 T CY121100921 T CY 121100921T CY 1113171 T1 CY1113171 T1 CY 1113171T1
Authority
CY
Cyprus
Prior art keywords
inflammating
factors
medicament
prevention
manufacture
Prior art date
Application number
CY20121100921T
Other languages
English (en)
Inventor
David John Grainger
David John Fox
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0327775A external-priority patent/GB0327775D0/en
Priority claimed from GB0417436A external-priority patent/GB0417436D0/en
Priority claimed from GB0417734A external-priority patent/GB0417734D0/en
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of CY1113171T1 publication Critical patent/CY1113171T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση αναφέρεται στη χρησιμοποίηση παραγώγων 3-αμινοκαπρολακτάμης για την παρασκευή ενός φαρμάκου με σκοπό την πρόληψη ή θεραπεία φλεγμονωδών διαταραχών, και χρησιμοποιεί ενώσεις του γενικού τύπου (I) ή φαρμακευτικώς αποδεκτά άλατα αυτών· όπου το Χ είναι -CO-R1 ή -SO2-R2, και τα R1 και R2 είναι ανθρακούχοι υποκατάστατες.
CY20121100921T 2003-12-01 2012-10-04 Αντιφλεγμονωδεις παραγοντες CY1113171T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0327775A GB0327775D0 (en) 2003-12-01 2003-12-01 Anti-inflammatory agents
GB0417436A GB0417436D0 (en) 2004-08-05 2004-08-05 Anti-inflammatory agents
GB0417734A GB0417734D0 (en) 2004-08-10 2004-08-10 Anti-Inflammatory agents
EP04798708A EP1691814B9 (en) 2003-12-01 2004-11-30 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
CY1113171T1 true CY1113171T1 (el) 2016-04-13

Family

ID=34657584

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100921T CY1113171T1 (el) 2003-12-01 2012-10-04 Αντιφλεγμονωδεις παραγοντες

Country Status (17)

Country Link
US (1) US20080227724A1 (el)
EP (2) EP2279741A3 (el)
JP (1) JP5248779B2 (el)
KR (1) KR101228268B1 (el)
CN (1) CN103393691A (el)
AR (1) AR047730A1 (el)
CA (1) CA2547651C (el)
CY (1) CY1113171T1 (el)
DK (1) DK1691814T3 (el)
ES (1) ES2390272T3 (el)
HK (1) HK1094680A1 (el)
IL (1) IL175857A0 (el)
PL (1) PL1691814T3 (el)
PT (1) PT1691814E (el)
SI (1) SI1691814T1 (el)
TW (1) TWI356821B (el)
WO (1) WO2005053702A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2418427A (en) * 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
AU2011226837B2 (en) * 2004-09-02 2014-09-18 Cambridge Enterprise Limited Ligands for G-protein coupled receptors
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
GB2455539B (en) * 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
CA2864797C (en) * 2012-02-15 2022-03-22 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
CN110325185A (zh) * 2017-01-18 2019-10-11 巴塞罗那自治大学 用于治疗神经退行性疾病和/或自身免疫性疾病的专门的促消退脂质介质

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB327775A (en) 1929-01-21 1930-04-17 John Harry Grayson Improvements in thermostats
NL37108C (el) 1933-06-02
US3697562A (en) * 1969-10-17 1972-10-10 Allied Chem Novel fluorocarbon diamides
JPS53121781A (en) * 1977-03-30 1978-10-24 Torii Yakuhin Kk Caprolactum derivatives
JPS625994A (ja) * 1985-07-02 1987-01-12 Toray Ind Inc リジン誘導体の製造法
EP0312157A3 (en) * 1987-10-13 1990-07-25 Merck & Co. Inc. Tetrapeptide renin inhibitors having a novel c-terminal amino acid
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
DK316989D0 (da) 1989-06-26 1989-06-26 Novo Nordisk As Enzymer
US5430022A (en) * 1990-05-14 1995-07-04 Fujisawa Pharmaceutical Co., Ltd. Peptide compound and its preparation
IT1247698B (it) * 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
IT1254471B (it) * 1992-02-27 1995-09-25 Magis Farmaceutici Derivati ammidici della (r)-glicerofosforil-(s)-serina o del suo diacil derivato, un processo per la loro preparazione e relative composizioni farmaceutiche per il potenziamento dei processi di apprendimento
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
SK282237B6 (sk) * 1995-02-22 2001-12-03 Novartis Ag Deriváty 1-aryl-2-acylaminoetánu, spôsob ich prípravy a farmaceutický prostriedok, ktorý ich obsahuje
SG64939A1 (en) * 1995-07-17 2002-02-19 Mitsui Chemicals Inc Olefin polymerization catalyst, process for preparing olefin polymer, and olefin polymer
JP3633060B2 (ja) 1995-09-22 2005-03-30 Ｊｓｒ株式会社 低結晶性エチレン系ランダム共重合体およびその組成物
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
WO1997021690A1 (en) * 1995-11-28 1997-06-19 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB9621836D0 (en) * 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
AU749658C (en) * 1996-12-23 2004-04-29 Elan Pharmaceuticals, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6506782B1 (en) * 1998-02-27 2003-01-14 Athena Neurosciences, Inc. Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
CN1181817C (zh) * 1998-03-20 2004-12-29 第一三得利制药株式会社 以苯基甲苯醌为有效成分的NF-kB抑制剂
US6395282B1 (en) 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
US6117870A (en) * 1998-11-12 2000-09-12 Fujirebio Kabushiki Kaisha Cyclic amide derivatives
EP2386565A3 (en) 1999-01-12 2013-11-20 Cambridge Enterprise Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2001068655A2 (en) * 2000-03-10 2001-09-20 Ariad Pharmaceuticals, Inc. Caprolactam derivatives and uses thereof

Also Published As

Publication number Publication date
KR101228268B1 (ko) 2013-01-31
EP1691814B9 (en) 2013-02-20
JP2007512387A (ja) 2007-05-17
AR047730A1 (es) 2006-02-15
TW200526585A (en) 2005-08-16
EP1691814B1 (en) 2012-07-25
PL1691814T3 (pl) 2012-12-31
PT1691814E (pt) 2012-10-16
CN103393691A (zh) 2013-11-20
CA2547651C (en) 2015-06-23
KR20070018807A (ko) 2007-02-14
US20080227724A1 (en) 2008-09-18
ES2390272T3 (es) 2012-11-08
HK1094680A1 (en) 2007-04-04
EP2279741A3 (en) 2011-06-01
SI1691814T1 (sl) 2012-11-30
DK1691814T3 (da) 2012-10-29
WO2005053702A3 (en) 2005-09-15
EP2279741A2 (en) 2011-02-02
IL175857A0 (en) 2008-02-09
EP1691814A2 (en) 2006-08-23
CA2547651A1 (en) 2005-06-16
JP5248779B2 (ja) 2013-07-31
TWI356821B (en) 2012-01-21
WO2005053702A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CY1113171T1 (el) Αντιφλεγμονωδεις παραγοντες
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1105441T1 (el) Ετepοκυκλικοι σουλφοναμιδικοι αναστολεις της παραγωγης βητα αμυλοειδους
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CY1115227T1 (el) Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase)
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
CY1105621T1 (el) Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1115533T1 (el) Παραγωγα χολικου οξεος ως προσδετες fxr για την προληψη ή τη θεραπευτικη αγωγη νοσηματων ή καταστασεων οι οποιες προκαλουνται με τη μεσολαβηση fxr
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1110580T1 (el) Νεα παραγωγα βενζοϊμιδαζολιου χρησιμα ως αντιπολλαπλασιαστικοι παραγοντες
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
CY1113766T1 (el) Παραγωγα ινδολιδονης για την θεραπεια ή προληψη ινωτικων ασθενειων
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1105047T1 (el) Ενωσεις πυριδοπυριμιδινονης, η μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τις περιεχουν
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
CY1123919T1 (el) 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp
CY1109348T1 (el) Διυδρο-θειενο-πυριμιδινες για τη θεραπεια φλεγμονωδων παθησεων
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα